Unicycive Therapeutics, Inc. (UNCY) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript [Seeking Alpha]
Kuehn Law Encourages Investors of Unicycive Therapeutics, Inc. to Contact Law Firm
Unicycive Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference
Unicycive Therapeutics (UNCY) had its price target lowered by Benchmark Co. from $21.00 to $15.00. They now have a "speculative buy" rating on the stock.
Unicycive Therapeutics (UNCY) had its price target lowered by Guggenheim from $46.00 to $40.00. They now have a "buy" rating on the stock.